Quantcast

Latest Biogen Idec Stories

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...

2013-10-17 23:19:38

Reportbuyer.com just published a new market research report: Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth. London (PRWEB) October 17, 2013 Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Summary GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis...

2013-10-10 23:23:12

Therapy Class Overview: Rituximab biosimilar is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) October 10, 2013 Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'